GlassScriptPhysician profile
Mark L Stevens
NPI 1427033786
$5,841.27
in general payments reported to CMS, 2019-2025
39 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,957 · 2020: $814 · 2021: $795 · 2022: $656 · 2023: $717 · 2024: $505 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.53 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $741.13 | 2019-2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $571.97 | 2019-2022 | |
| Abbvie INC. | $476.22 | 2022-2025 | Avycaz, Ubrelvy |
| Lilly USA, LLC | $390.11 | 2020-2023 | Mounjaro |
| Astellas Pharma US INC | $360.57 | 2019-2024 | Veozah, Myrbetriq |
| La Jolla Pharmaceutical Company | $331.26 | 2021-2025 | Xerava, Zevtera |
| E.R. Squibb & Sons, L.L.C. | $259.63 | 2021-2023 | Camzyos, Eliquis |
| Ferring Pharmaceuticals INC. | $220.99 | 2022-2023 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.99 | 2019-2021 | |
| Allergan, INC. | $194.28 | 2019 | |
| Paratek Pharmaceuticals, INC. | $191.36 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $183.75 | 2019 | |
| Pfizer INC. | $172.56 | 2019-2021 | |
| Medtronic USA, INC. | $165.46 | 2019 | |
| Organogenesis INC. | $140.96 | 2022-2025 | Affinity |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.